Drug
Selexipag clinical trials
Also written ACT-293987, JNJ-67896049 and Uptravi.
- studies test it
- 25
- open now
- 1
- in phase 3
- 9
- first study started
- 2009
Keep track of what changes. Save the selexipag studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
- Phase 3
- 9
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 2
Actelion (21) · Humanis Saglık Anonim Sirketi (2) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Sao Paulo General Hospital (1)
Often tested with
Tested in the same studies.
Riociguat (1) · Sotatercept (1) · Clopidogrel (1) · Gemfibrozil (1) · Rifampin (1) · Midazolam (1) · Moxifloxacin (1) · Macitentan (1)
Studies
Open first, then newest update. How each study uses selexipag is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingPhase 3ActelionNCT05179876Written as Selexipag
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial HypertensionActive, not recruitingPhase 3ActelionNCT04175600Written as Selexipag
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruitingPhase 2ActelionNCT03492177Written as selexipag (Uptravi)
- Pulmonary Hypertension: Intensification and Personalisation of Combination RxActive, not recruitingPhase 4Sheffield Teaching Hospitals NHS Foundation TrustNCT05825417Written as Selexipag
- Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated TabletsCompletedPhase 1Humanis Saglık Anonim SirketiNCT07694128Written as Selexipag Film Coated Tablets (T1)
- Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedPhase 2ActelionNCT02260557Written as Selexipag
- Selexipag (ACT-293987) in Pulmonary Arterial HypertensionCompletedPhase 3ActelionNCT01106014Written as Selexipag
- Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial HypertensionCompletedPhase 3ActelionNCT03187678Written as i.v. selexipag
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male SubjectsCompletedPhase 1ActelionNCT03496506Written as Selexipag
- A Study of Selexipag in Participants Who Participated in a Previous Selexipag StudyCompletedPhase 3ActelionNCT04565990Written as Selexipag
- Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)CompletedPhase 1Humanis Saglık Anonim SirketiNCT06932198Written as Selexipag Film Coated Tablets
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedPhase 3ActelionNCT02558231Written as Selexipag
- Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedPhase 4ActelionNCT03078907Written as Selexipag
- ACT-293987 in Pulmonary Arterial HypertensionCompletedPhase 3ActelionNCT01112306Written as ACT-293987
- A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedPhase 4ActelionNCT04435782Written as JNJ-67896049
- Comparison of Two Dose Strengths of Selexipag in Healthy AdultsCompletedPhase 1ActelionNCT02745860Written as Selexipag (adult formulation)
- Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy SubjectsCompletedPhase 1ActelionNCT02882425Written as Selexipag for intravenous use
- A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy SubjectsCompletedPhase 1ActelionNCT02770222Written as Selexipag
- Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μgCompletedPhase 1ActelionNCT02206295Written as selexipag
- A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional TreatmentTerminatedPhase 3ActelionNCT03689244Written as Selexipag
See all 25 studies that test selexipag →
Given in every arm · 1 — selexipag is usual care beside what is tested
Codes
What other systems call selexipag · ClinicalTrials.gg INT005165
- MeSH (NLM) C523468selexipagConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5EXC0E384LSELEXIPAGConfirmed FDA, NLM, Wikidata
- RxNorm 1729002Confirmed FDA, Wikidata
- Wikidata Q15424759selexipagConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152321SelexipagOne source FDA
- DrugBank DB11362One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523468 | selexipag | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5EXC0E384L | SELEXIPAG | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1729002 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15424759 | selexipag | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152321 | Selexipag | One source FDA |
| DrugBank | DB11362 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.